Evidence map›Paper›PMID 41832613›Full record

ArticleThe Journal of physiology2026

Regulation of basal and tumour necrosis factor α-induced fibroblast gene expression by peptidylarginine deiminase 2.

Mohammad Aslam Saifi, Flavien Marguerie, Mari Kamiya, Hung N Nguyen, Rachel S Knipe, Edy Y Kim, I-Cheng Ho

Abstract read
In one paragraph

Article in The Journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohammad Aslam SaifiDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Flavien MarguerieDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Mari KamiyaHarvard Medical School, Boston, Massachusetts, USA.
Hung N NguyenDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Rachel S KnipeHarvard Medical School, Boston, Massachusetts, USA.
Edy Y KimHarvard Medical School, Boston, Massachusetts, USA.
I-Cheng HoDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Funding

Loss of Endothelial S1PR1 Drives Post-Influenza Pulmonary FibrosisR01HL168138 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel S Knipe · 2023 to 2026
$2.9M
Regulatory roles of peptidylarginine deimination in elastogenisisR01HL158601 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HO, I-CHENG · 2022 to 2025
$2.2M
American Lung Association DA-827785NHLBI NIH HHS R01 HL158601NHLBI NIH HHS R01 HL168138NIH HHS HL158601NIH HHS HL 168138
6 · The paper itself

Abstract

Fibroblasts exhibit organ-specific function and in response to tumour necrosis factor α (TNFα) can produce a large amount of inflammatory mediators, including interleukin-6 (IL-6), partly via a leukaemia inhibitory factor (LIF) autocrine loop, thereby playing a critical pathogenic role in several organ-specific autoimmune diseases, such as rheumatoid arthritis (RA). Peptidylarginine deiminases (PADs), including PAD1-4 and PAD6 in humans, irreversibly convert peptidylarginine to non-coding peptidylcitrulline, a process also known as citrullination. Although the behaviour of fibroblasts is influenced by the citrullination status of extracellular matrix proteins, whether PADs cell-autonomously regulate gene expression of fibroblasts is still unclear. Interestingly heightened PAD activity is strongly associated with RA, which often co-occurs with interstitial lung disease (ILD). The molecular mechanism mediating the unique lung-synovium connection in RA is still poorly understood. Here we show that PAD2 transcript levels in lung fibroblasts (LFs) increased with age, a trend not observed with other PADs or in fibroblasts from other organs. PAD2 deficiency reduced the expression of Podoplanin and Tumor necrosis factor receptor superfamily member 1B (TNFRSF1b) across fibroblasts from all mouse organs and human LFs. Additionally PAD2 deficiency attenuated the expression of several LIF-dependent and LIF-independent genes, including chemokines and Il6, in LFs after TNFα stimulation. Particularly a reduction in TNFα-induced interleukin-6 (IL-6) expression was also detected in fibroblasts from synovium but not in fibroblasts from other organs. These findings demonstrate that PAD2 regulates TNFα-induced gene expression of fibroblasts depending on their organ origin, suggest a novel pathogenic role for PAD2 in RA and offer a plausible explanation for the observed lung-synovium connection. KEY POINTS: Fibroblasts in response to tumour necrosis factor α (TNFα) produce a high level of inflammatory cytokine interleukin-6 (IL-6) that drives the joint and often lung inflammation seen in rheumatoid arthritis (RA), which is characterized by autoimmunity against citrullinated antigens produced by peptidylarginine deiminases (PADs). Fibroblast-derived PAD2 can citrullinate extracellular matrix proteins (ECMPs), whereas the citrullination status of ECMPs reciprocally influences the behaviour of fibroblasts. We examined the cell-autonomous role of PAD2 in fibroblast gene expression and found that PAD2 levels uniquely increase with age in lung fibroblasts (LFs) but not fibroblasts from other organs. PAD2 maintains the expression of Podoplanin and Tumor necrosis factor receptor superfamily member 1B (TNFRSF1b) in fibroblasts across multiple organs but promotes basal and TNFα-induced IL-6 expression in lung and synovial fibroblasts. These results suggest a novel pathogenic role for fibroblast-derived PAD2 in RA and offer a plausible explanation for the unique tissue tropism of RA.

Indexed as

citrullinationfibroblastsinterleukin‐6 (IL‐6)leukaemia inhibitory factorpeptidylarginine deiminase 2Podoplaninrheumatoid arthritistumour necrosis factor α (TNFα)

Identifiers

PMID41832613
PMCPMC12991426

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.